Loading
NYSEHealthcareMedical - Instruments & Supplies
Latest quote
$24.35
+$0.45 · +1.88%
Baxter International Inc., operating globally via its subsidiaries, is a leading developer and provider of a wide spectrum of healthcare products. The company's comprehensive portfolio includes various dialysis treatments, such as peritoneal and hemodialysis, along with related therapies and services. It also specializes in intravenous (IV) therapies, infusion pumps, administration sets, and devices for drug reconstitution. Further expanding its pharmaceutical offerings, Baxter delivers pre-mixed and oncology drug platforms, inhaled anesthetic agents, critical care products, and pharmacy compounding services. Nutritional support is provided through its parenteral nutrition therapies and associated products. For surgical procedures, the company develops biological products and medical devices vital for achieving hemostasis, tissue sealing, and preventing adhesions. Additionally, Baxter supplies continuous renal replacement therapies (CRRT) and other organ support solutions, primarily tailored for intensive care units. Beyond direct medical supplies, Baxter provides sophisticated connected care solutions, integrating devices, software, communication systems, and other advanced technologies. This includes a range of patient monitoring and diagnostic technologies designed to aid in the diagnosis, treatment, and management of numerous illnesses and conditions, spanning respiratory therapy, cardiology, vision screening, and physical assessment. The surgical suite benefits from its specialized video technologies, operating tables, lights, pendants, precision positioning tools, and various ancillary accessories. The company also offers contracted services to a multitude of pharmaceutical and biopharmaceutical companies. Baxter's products are utilized across diverse healthcare environments, including hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and for home-based patients under medical supervision. Operating in approximately 100 countries, Baxter distributes its extensive product line through a direct sales force, independent distributors, drug wholesalers, and specialty pharmacies or other alternative site providers. The company also holds a collaborative agreement with Celerity Pharmaceutical, LLC, focused on developing generic injectable pre-mixed medications for acute care and oncolytic molecules. Established in 1931, Baxter International Inc. is headquartered in Deerfield, Illinois.
Previous close
$24.35
+$0.45 · +1.88%
Regular session · ET · Market data may be delayed.
Baxter International Inc., operating globally via its subsidiaries, is a leading developer and provider of a wide spectrum of healthcare products. The company's comprehensive portfolio includes various dialysis treatments, such as peritoneal and hemodialysis, along with related therapies and services. It also specializes in intravenous (IV) therapies, infusion pumps, administration sets, and devices for drug reconstitution. Further expanding its pharmaceutical offerings, Baxter delivers pre-mixed and oncology drug platforms, inhaled anesthetic agents, critical care products, and pharmacy compounding services. Nutritional support is provided through its parenteral nutrition therapies and associated products. For surgical procedures, the company develops biological products and medical devices vital for achieving hemostasis, tissue sealing, and preventing adhesions. Additionally, Baxter supplies continuous renal replacement therapies (CRRT) and other organ support solutions, primarily tailored for intensive care units. Beyond direct medical supplies, Baxter provides sophisticated connected care solutions, integrating devices, software, communication systems, and other advanced technologies. This includes a range of patient monitoring and diagnostic technologies designed to aid in the diagnosis, treatment, and management of numerous illnesses and conditions, spanning respiratory therapy, cardiology, vision screening, and physical assessment. The surgical suite benefits from its specialized video technologies, operating tables, lights, pendants, precision positioning tools, and various ancillary accessories. The company also offers contracted services to a multitude of pharmaceutical and biopharmaceutical companies. Baxter's products are utilized across diverse healthcare environments, including hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and for home-based patients under medical supervision. Operating in approximately 100 countries, Baxter distributes its extensive product line through a direct sales force, independent distributors, drug wholesalers, and specialty pharmacies or other alternative site providers. The company also holds a collaborative agreement with Celerity Pharmaceutical, LLC, focused on developing generic injectable pre-mixed medications for acute care and oncolytic molecules. Established in 1931, Baxter International Inc. is headquartered in Deerfield, Illinois.
Day range
Current $24.35
52-week range
Current $24.35
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
32
Expensive
Sentiment
62
Bullish
Risk
36
Moderate Risk
Momentum
54
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Baxter International Inc., operating globally via its subsidiaries, is a leading developer and provider of a wide spectrum of healthcare products. The company's comprehensive portfolio includes various dialysis treatments, such as peritoneal and hemodialysis, along with related therapies and services. It also specializes in intravenous (IV) therapies, infusion pumps, administration sets, and devices for drug reconstitution. Further expanding its pharmaceutical offerings, Baxter delivers pre-mixed and oncology drug platforms, inhaled anesthetic agents, critical care products, and pharmacy compounding services. Nutritional support is provided through its parenteral nutrition therapies and associated products. For surgical procedures, the company develops biological products and medical devices vital for achieving hemostasis, tissue sealing, and preventing adhesions. Additionally, Baxter supplies continuous renal replacement therapies (CRRT) and other organ support solutions, primarily tailored for intensive care units. Beyond direct medical supplies, Baxter provides sophisticated connected care solutions, integrating devices, software, communication systems, and other advanced technologies. This includes a range of patient monitoring and diagnostic technologies designed to aid in the diagnosis, treatment, and management of numerous illnesses and conditions, spanning respiratory therapy, cardiology, vision screening, and physical assessment. The surgical suite benefits from its specialized video technologies, operating tables, lights, pendants, precision positioning tools, and various ancillary accessories. The company also offers contracted services to a multitude of pharmaceutical and biopharmaceutical companies. Baxter's products are utilized across diverse healthcare environments, including hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and for home-based patients under medical supervision. Operating in approximately 100 countries, Baxter distributes its extensive product line through a direct sales force, independent distributors, drug wholesalers, and specialty pharmacies or other alternative site providers. The company also holds a collaborative agreement with Celerity Pharmaceutical, LLC, focused on developing generic injectable pre-mixed medications for acute care and oncolytic molecules. Established in 1931, Baxter International Inc. is headquartered in Deerfield, Illinois.
Day range
Current $24.35
52-week range
Current $24.35
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 11.24B USD | 10.64B USD | 10.36B USD | 10.06B USD | 12.15B USD |
| Cost of goods sold | 7.87B USD | 6.65B USD | 6.21B USD | 6.51B USD | 7.43B USD |
| Gross profit | 3.38B USD | 3.98B USD | 4.15B USD | 3.55B USD | 4.72B USD |
| Research and development | 518M USD | 590M USD | 518M USD | 450M USD | 531M USD |
| Selling, general, and administrative | 2.89B USD | 2.97B USD | 2.95B USD | 3.1B USD | 2.85B USD |
| Operating expenses | 3.69B USD | 3.97B USD | 3.44B USD | 6.39B USD | 3.37B USD |
| Interest income | 52M USD | 67M USD | 69M USD | 19M USD | 14M USD |
| Interest expense | 290M USD | 408M USD | 508M USD | 413M USD | 207M USD |
| Depreciation and amortization | 981M USD | 997M USD | 984M USD | 1.07B USD | 867M USD |
| Operating income | −308M USD | 14M USD | 707M USD | −2.85B USD | 1.35B USD |
| Net income | −957M USD | −649M USD | 2.66B USD | −2.43B USD | 1.28B USD |
Company facts updated Oct 10, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$23.60
3.08% downsidePrice history unavailable
High $28.00Average $23.60Low $20.00| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Jul 1, 2015 | 1,841:1,000 | — | — |
Stock split | May 31, 2001 | 2:1 | — | — |
Stock split | Dec 1, 1992 | 100,000:90,823 | — | — |
Stock split | Nov 18, 1983 | 2:1 | — | — |
Stock split | Nov 9, 1981 | 2:1 | — | — |
Effective Jul 1, 2015
1,841:1,000
Effective May 31, 2001
2:1
Effective Dec 1, 1992
100,000:90,823
Effective Nov 18, 1983
2:1
Effective Nov 9, 1981
2:1
Funds reporting this stock among their holdings, ordered by reported position size.
State Street SPDR S&P 500 ETF1557.T24.15B0.02%129.34T JPY0.09%¥122,850+0.12%
Vanguard Morningstar Total Stock Market ETFVTI427.26M0.02%2.3T USD0.03%$381.94+0.63%
Vanguard S&P 500 ETFVOO356.75M0.02%1.8T USD0.03%$715.59+0.61%
Vanguard Morningstar Small-Cap ETFVB308.83M0.16%185.3B USD0.03%$289.48+0.64%
Invesco S&P 500 Equal Weight ETFRSP191.38M0.20%96.75B USD0.20%$213.04+0.55%
Vanguard Morningstar Small-Cap Value ETFVBR177.44M0.26%68.2B USD0.05%$234.43+0.22%
iShares Core S&P 500 ETFIVV164.26M0.02%892.79B USD0.03%$781.97+0.60%
State Street SPDR S&P 500 ETFSPY152.61M0.02%817.2B USD0.09%$778.57+0.60%State Street SPDR S&P 500 ETF1557.TVanguard Morningstar Total Stock Market ETFVTIVanguard S&P 500 ETFVOOVanguard Morningstar Small-Cap ETFVBInvesco S&P 500 Equal Weight ETFRSPVanguard Morningstar Small-Cap Value ETFVBRiShares Core S&P 500 ETFIVVState Street SPDR S&P 500 ETFSPYAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
